TriSalus Life Sciences, Inc.
TLSI- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001826667
In the last 90 days, TriSalus Life Sciences, Inc. insiders filed 1 open-market purchase and 3 sales; 78 institutions reported holding it in 13F filings for Q2 2026, worth $99.0M in total; no superinvestor holds it.
Other share classesTLSIW
Key figures
- Market capClose on Nov 17, 2026
- $141.6M
- Insider buysLast 90 days, $112.0K in total
- 1
- Insider sellsLast 90 days, $4.11K in total
- 3
- 13F holdersQ2 2026, −4 vs. previous quarter
- 78
- 13F valueReported value at the end of Q2 2026
- $99.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $45.2M
- +53.4% year over year
- Net income, FY2025
- -$39.2M
- No comparable prior period
- Free cash flow, FY2025
- -$18.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $12.9M
- +11.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $39.2M (86.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.31M
- Shares sold short
- Change
- −132.3K
- −3.8% vs. previous
- Days to cover
- 28.45
- At average daily volume
Superinvestors holding TLSI, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TLSI at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by TriSalus Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 (view filing)8:16 AM ET | Nov 12 | 4 days | Wahlstrom MatsDirector | PPurchase | +50.0K | $2.24 | +$112.0K | +33.9%197.6K after | |
| Oct 7, 2026 (view filing)4:02 PM ET | Oct 5 | 2 days | Cox Bryan F.Chief of Research | SSale | −296 | $4.39 | −$1.30K | −0.2%162.8K after | |
| Oct 7, 2026 (view filing)4:02 PM ET | Oct 5 | 2 days | Marshak RichardChief Commercial Officer | SSale | −325 | $4.39 | −$1.43K | −0.3%128.0K after | |
| Oct 7, 2026 (view filing)4:02 PM ET | Oct 5 | 2 days | Stevens JenniferChief Regulatory Officer | SSale | −316 | $4.39 | −$1.39K | −0.3%123.8K after | |
| May 19, 2026 (view filing) | May 15 | 4 days | Marshak RichardChief Commercial Officer | SSale | −543 | $2.67 | −$1.45K | −0.4%125.1K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Wahlstrom MatsDirector | PPurchase | +60.0K | $2.53 | +$151.8K | +68.5%147.6K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +410.0K | $2.50 | +$1.02M | +49.4%1.24M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +200.0K | $2.50 | +$500.0K | +100.2%399.7K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Szela Mary TCEO and President | PPurchase | +39.7K | $2.59 | +$102.8K | +3.9%1.07M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Patience DavidChief Financial Officer | PPurchase | +7.10K | $2.43 | +$17.3K | +2.6%275.8K after |
Top 10 13F holders, Q2 2026
See all 78 holdersThe largest institutional positions in TriSalus Life Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| First Light Asset Management, LLC | 6,552,491 | $29.8M | 1.81% | +1,485,664+29.3% | Added |
| BlackRock, Inc. | 2,659,218 | $12.1M | 0.00% | +1,159,671+77.3% | Added |
| Vanguard Capital Management LLC | 1,729,385 | $7.87M | 0.00% | +382,349+28.4% | Added |
| Cerity Partners LLC | 1,603,538 | $7.30M | 0.01% | +816,266+103.7% | Added |
| Geode Capital Management, LLC | 1,190,067 | $5.42M | 0.00% | +412,973+53.1% | Added |
| Nantahala Capital Management, LLC | 1,000,000 | $4.55M | 0.27% | −1,070,827−51.7% | Reduced |
| Gilder Gagnon Howe & Co LLC | 850,081 | $3.87M | 0.04% | −38,434−4.3% | Reduced |
| State Street Corp | 610,963 | $2.78M | 0.00% | +282,943+86.3% | Added |
| White Pine Capital LLC | 547,577 | $2.49M | 0.59% | +347,732+174.0% | Added |
| Thompson Siegel & Walmsley LLC | 536,534 | $2.44M | 0.04% | −47,040−8.1% | Reduced |
Holders of 5% or more of TLSI
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of TriSalus Life Sciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Frankenius Equity AB | 13D/A | 14.00%6.99M shares | −6.50 ppfrom 20.50% | Aug 21, 20234 filings | Aug 4, 2025 | SEC |
| First Light Asset Management, LLC | 13G/A | 12.00%7.41M shares | +1.26 ppfrom 10.74% | May 15, 20263 filings | Nov 16, 2026 | SEC |
| Wahlstrom Mats | 13D/A | 6.00%2.99M shares | −3.00 ppfrom 9.00% | Aug 21, 20233 filings | Aug 1, 2025 | SEC |
| Utmost Group Plc | 13G | 5.71%3.50M shares | −1.08 ppfrom 6.79% | Aug 18, 20253 filings | May 12, 2026 | SEC |
| Pallotta James J | 13G/A | 5.20%3.19M shares | – | Dec 4, 20242 filings | May 20, 2026 | SEC |